Clinical Trials
676
30 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1948
Active, not recruiting
10
1.5%
Completed
193
28.6%
Enrolling By Invitation
3
0.4%
Not yet recruiting
17
2.5%
Recruiting
51
7.5%
Suspended
7
1.0%
Terminated
26
3.9%
Unknown
335
49.6%
Withdrawn
34
5.0%
No approval data available
- A retrospective analysis of 97 high-risk/hard-to-treat pediatric cancer patients at Sheba Medical Center (2016–2021) identified 386 variants, with TP53 and ATM as the most frequently mutated genes. - Nearly one in four patients (23.7%) received therapeutic or monitoring recommendations based on NGS results, and 70% of those treated with precision medicine in the first line required no additional therapy. - Seven of the 17 most prevalent variants were actionable, including ATM p.P604S (Olaparib), EWSR1-FLI1 fusion (TK216), and TP53 p.G245S (MDM2 inhibitor AMGMDS3). - The study highlights population-specific mutations in the Israeli pediatric population and supports routine implementation of NGS early in the treatment course rather than only after standard options are exhausted.
- Sheba Medical Center has delivered TIL therapy for over 15 years, treating more than 200 melanoma patients through its established clinical program. - The withdrawal of a commercial manufacturer's EMA application has left European patients with limited access to TIL therapy outside of highly selective clinical trials. - Sheba's Advanced Biotherapy Center enables on-site GMP-compliant manufacturing, with its CAR-T program achieving a 98.8% manufacturing success rate and an 11-day vein-to-vein time. - The medical center, ranked #7 globally by Newsweek in 2026, offers dedicated international patient support including native-language coordination and travel logistics assistance.
- Sheba Medical Center in Israel has signed a strategic partnership with OpenAI, becoming the first hospital outside the United States to access the company's dedicated healthcare AI models. - The agreement covers OpenAI for Healthcare and ChatGPT Health, encrypted platforms designed to support clinical decision-making and treatment plan development based on medical research. - Sheba clinicians will receive early access to unreleased AI models, participate in product development, and integrate the hospital's clinical protocols into OpenAI's systems. - The platform provides cited references and journal sources, enabling physicians to independently verify the evidence underlying each AI-generated recommendation.
- Teva Pharmaceutical Industries and ARC Innovation at Sheba Medical Center signed a collaboration agreement to help Israeli health tech startups scale from pilots to global markets. - The partnership focuses on three areas: startup access to both organizations, clinical R&D collaboration, and logistics/operations including cold-chain and supply-chain challenges. - Both organizations won Israel Innovation Authority grants in December, which accelerated discussions and created converging paths for the collaboration. - A joint steering committee will meet quarterly with project budgets set individually, ranging from tens of thousands to millions of dollars.
- XTL Biopharmaceuticals announced acquisition of Psyga Bio for 40% equity stake, positioning the company as a leading psychedelic biotechnology platform with seven approved Phase 2a clinical trials. - The transaction follows President Trump's April 18, 2026 Executive Order directing FDA to accelerate psychedelic therapy research and approval pathways for serious mental illness treatment. - Psyga operates a licensed GMP-ready manufacturing facility for psilocybin and ibogaine production, with a proprietary library of over 180 unique mushroom strains. - The deal includes milestone-based earnouts totaling 30% additional equity tied to clinical trial commencement, target achievement, and ibogaine commercialization partnerships.
- ClearNote Health's Avantect Pancreatic Cancer Test demonstrates industry-leading detection sensitivity of 82.6% and specificity of 97.5% for patients at elevated risk of pancreatic cancer. - The blood-based test utilizes the company's Virtuoso epigenomics platform, which measures 5-hydroxymethylcytosine (5hmC) biomarkers in cell-free DNA combined with AI algorithms for early cancer detection. - The test is being incorporated into major international studies including the NHS-led SAFE-D study and the Pancreatic Cancer Early Detection (PRECEDE) Consortium for risk-stratified screening. - ClearNote Health will present new data at both the AACR Annual Meeting 2026 and Digestive Disease Week 2026, showcasing advances in liquid biopsy technology for one of oncology's most challenging cancers.
- The U.S. Department of Defense has awarded up to $11 million to fund a clinical trial investigating the combination of vedolizumab with CurQD, a plant-based formulation containing curcumin and QingDai, for ulcerative colitis treatment. - The trial addresses the significant burden of ulcerative colitis in military populations, where incidence rates are nearly 50% higher than in the general population, affecting over 35,000 military healthcare beneficiaries. - Current ulcerative colitis treatments plateau at approximately 50% response rates, prompting researchers to explore whether combining pharmaceutical and nutraceutical approaches may improve patient outcomes. - The international collaboration involves Mount Sinai Hospital, University of Chicago Medicine, and Sheba Medical Center, representing a novel approach to IBD treatment that addresses patient preferences for complementary natural compounds.
- Starget Pharma completed an $18 million Series A funding round to advance its Smart Targeted Radioligands (STRs) for precision oncology therapies. - The company will begin advanced clinical trials this year in collaboration with MD Anderson Cancer Center for a first-of-its-kind treatment targeting sarcoma, skin cancer, and neuroendocrine tumors. - Starget's AI-based discovery platform enables faster development of precision radioactive drugs that use the same molecule for both diagnosis and treatment. - The funding brings the company's total raised to $38 million since its founding in 2019, supporting expansion of development and manufacturing infrastructure in the US.
- MediWound announced peer-reviewed clinical data showing NexoBrid® reduced pigmented wound surface by 92.5% in patients with traumatic tattoos from friction and blast injuries. - The prospective study of 15 patients at Sheba Medical Center demonstrated that NexoBrid® removed 96% of visible pigments in abrasive injuries and 84% in explosive injuries. - The enzymatic debridement treatment was well-tolerated with no adverse events, offering a precision alternative to aggressive mechanical scrubbing for embedded particle removal. - This represents the first published series evaluating enzymatic debridement for traumatic tattoo prevention, supporting further evaluation in acute trauma settings.
- Precise Bio successfully implanted PB-001, the world's first 3D-bioprinted corneal implant, in a legally blind patient at Rambam Medical Center in Israel on October 29, 2025. - The breakthrough implant is manufactured entirely from cultured human corneal cells using proprietary 3D-bio-fabrication technology, potentially transforming corneal transplantation from donor-dependent to lab-grown solutions. - The Phase 1 clinical trial will evaluate safety and tolerability in 10-15 patients with corneal edema, with topline results expected in the second half of 2026. - This milestone addresses the global shortage affecting over 13 million patients awaiting corneal tissue by enabling scalable production of corneal implants from a single donor source.
